Kornimate/medical-research-clean huggingface dataset:
evaluation of matrix metalloproteinase 8 salivary test for diagnosis of periodontitis

Conditions: Periodontitis; Gingivitis; Infertility

Summary: despite the great progress in understanding the causes of infertility, the reason for the failure of pregnancy has not been discovered among 25% of infertile couples. some studies have shown the negative impact of periodontal disease on the reproductive potential of women. it is known that there is an elevated level of matrix metalloproteinase 8 (mmp8) in the gingival fluid of patients with periodontitis. it is possible to establish a fast diagnosis of periodontitis by using a non-invasive assay based on monoclonal antibodies to two epitopes of mmp-8. the goal of the research is to use the above described assay in order to compare the level of mmp8 in the gingival fluid of infertile patients with the control group of fertile women, depending on the existence of periodontal disease. it is expected to find significantly higher values of mmp8 in infertile patients in relation to the fertile patient with/without periodontitis. the prompt treatment of periodontitis in preconception care of this group of women could have a significant impact on the improvement of fertility and ability to achieve pregnancy.

periodontal disease or periodontitis is a common chronic infection and inflammatory gingival disease and its supportive tissue associated with several unwanted effects, including serious obstetric consequences. periodontitis is commonly diagnosed in clinical practice based on clinical findings and radiological examinations, but also with the help of microbiological or periodontal bacterial specimens. several salivary markers have been investigated and it appears that the determination of matrix metalloproteinases provides clear information on the difference between gingivitis, periodontitis, and healthy periodontitis. especially in this respect, matrix metalloproteinase 8 (mmp 8) was investigated, which proved to be a fairly good marker. little is known about the effect of periodontitis on reproductive potential of women. some studies have assumed that periodontitis could be one of the possible risk factors of infertility of an unknown cause. one of the possible mechanisms responsible for the negative influence of periodontitis is the conception of the mediator of inflammation at the level of the endometrium and the place of implantation of the embryo.the aim of the study was to compare the level of mmp8 in salivary fluid in infertile patients in relation to the control group of fertile women, depending on the existence of periodontitis.

Eligibility criteria:
inclusion criteria: * fertile women- women who gave birth to at least one child, without previous fertility treatments, with or without periodontitis * infertile women- women who are diagnosed with infertility of unknown cause, with or without periodontitis exclusion criteria: * female with known cause of infertility
incobotulinumtoxina (xeomin) versus placebo in the treatment of cervical dystonia

Conditions: Cervical Dystonia

Summary: at baseline patients received incobotulinumtoxina (xeomin) or placebo. thereafter, all patients who entered the extension period were treated with up to five injection sessions of incobotulinumtoxina (xeomin) during the extension period.


Eligibility criteria:
main inclusion criteria: * male or female outpatients between ages 18 and 75 years inclusive) * a clinical diagnosis of cervical dystonia (i.e. spasmodic torticollis) with predominantly rotational form and a need for injection (determined by the toronto western spasmodic torticollis rating scale (twstrs) -total score) * twstrs-total score \>= 20 * twstrs-severity score \>= 10 * twstrs-disability score \>= 3 * twstrs-pain score \>= 1 * on a stable dose of medications (if any) used for focal dystonia treatment (e.g. anticholinergics and benzodiazepines) for at least 3 months prior to and expected throughout the main period * for pre-treated patients only: source documentation of the last two consecutive injection sessions with botulinum toxin and stable therapeutic response directly prior to trial entry * for pre-treated patients only: at least 10 weeks must have been passed between the last injection with botulinum toxin for cervical dystonia and baseline * for pre-treated patients only: the most recent injection with botulinum toxin must have been maximal 300 units of type a or 12,000 units of type b main exclusion criteria: * traumatic torticollis or tardive torticollis * twstrs-severity score for anterocollis \>= 2 points (pure anterocollis) * twstrs-severity score for retrocollis \>= 2 points (pure retrocollis) * myotomy or denervation surgery in the affected muscles (e.g. peripheral denervation and/or spinal cord stimulation) * hypersensitivity to human serum albumin, sucrose, or botulinum toxin type a * diagnosis of myasthenia gravis, lambert-eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease which might interfere with the trial * current swallowing disorder of any origin (dysphagia scale \>= 3, i.e. severe, with swallowing difficulties and requiring a change in diet) * marked limitation on passive range of motion that suggests contractures or other structural abnormality, e.g. cervical contractures or cervical spine syndrome * treatment with botulinum toxins for any indication other than cervical dystonia within 4 months prior to baseline and during the trial
international classification of functioning, disability and health and lower extremity orthoses in cerebral palsy

Conditions: Cerebral Palsy

Summary: international classification of functioning, disability and health (icf) is a coding system developed to describe the health status of individuals in a universal way. the increasingly common core sets are short forms of icf categories that are specifically selected for diseases. the aim of this study is to investigate the relationship among the lower extremity orthoses commonly used in children with cerebral palsy (cp), body structure and functions, activity and participation level, and is to determine the relationship between clinical tests and icf cp core set. for this purpose, a total of 75 children with ages between 3 and 18 will be divided into 3 groups, including using a walking orthosis, using a resting orthosis, and using both walking and resting orthoses. children's muscle tone, joint limitation, gross motor functions, balance skills, activity and participation levels and quality of life will be assessed with the tests frequently used in the clinic separately and with the core set in a holistic framework.


Eligibility criteria:
inclusion criteria: * being 3-18 age years old * having the diagnosis with cerebral palsy * being no botulinum toxin application or no surgery for the last 6 months exclusion criteria: * if there is any other neurological or orthopedic problem other than cerebral palsy

Keywords: cerebral palsy lower extremity orthosis icf core set
oral dexamethasone for the management of symptomatic irreversible pulpitis without performing pulpotomy

Conditions: Irreversible Pulpitis

Summary: the efficacy of short course orally administered dexamethasone on the reduction of pain before conventional pulpotomy has not yet been demonstrated. therefore, the aim of this randomized clinical study is to assess the effect of dexamethasone on the reduction of pain in mandibular molars with irreversible pulpitis, without performing conventional pulpotomy in comparison to pain following pulpotomy.


Eligibility criteria:
inclusion criteria: systemically healthy patients (category: american society of anesthesiologists class 1) (asa house of delegates 2014) aged between 18 and 40 years with mandibular molars diagnosed with symptomatic irreversible pulpitis and a radiographically normal periapical region were included. diagnosis was based on clinical and radiographic examination and pulp sensibility testing. teeth were included if they responded long-term to cold test, the cold test was performed by injecting a syringe filled with cold water at the level of the suspicious tooth and the adjacent teeth. teeth with deep occlusal decay, old restoration with underlying decay, recent restoration or crown were included. patients that agreed to be contacted by phone after the emergency visit until pain relief, that were available to come back after the emergency visit for complete endodontic treatment and who had the ability to understand the informed consent form and pain recording scales used within this study were included. exclusion criteria: teeth with acute or chronic apical abscess, pulp necrosis, septum syndrome and open apices were excluded. medically compromised patients, pregnant and lactating women were excluded. patients having history of allergy to local anesthetic solutions or any of the experimental drugs, on long-term medications that influenced pain threshold, analgesics, steroids and/or antibiotics in the recent past 24 h, were also excluded from the trial. patients that suffered from a viral disease in evolution (hepatitis, herpes zoster, ocular herpes), have or had a history of tuberculosis, hypertension, renal insufficiency, adrenocortical dysfunction, epilepsy, systemic fungal infections, guillain-barre syndrome, peptic ulcers and gastro intestinal disorders were excluded. patients with temporomandibular joint disorders were excluded. patients suffering from mental disabilities were also excluded.

Keywords: "irreversible pulpitis " "mandibular molars " "pain" "pulpotomy" "dexamethasone"
image-guided and intensity-modulated radiotherapy versus external beam radiotherapy for patients with spine metastases

Conditions: Vertebral Bony Metastases

Summary: the aim of this explorative trial is to verify the comparability of a fractionated intensity modulated radiotherapy with a conventional radiotherapy related to quality of life on the one hand and to evaluate toxicity, re-calcification and stability of vertebral body as well as pain relief and local response for palliative patients with painful spinal bone metastases on the other hand. this is a single-center, prospective randomized controlled trial with parallel-group design to determine the quality of life after rt in patients with spinal bone metastases. two different techniques were evaluated: intensity modulated radiotherapy (imrt) and fractionated conventional external beam rt with 10×3 gy each. experimental intervention: imrt 10 x 3 gy control intervention: 3d-rt 10 x 3 gy

the aim of this explorative trial is to verify the comparability of a fractionated intensity modulated radiotherapy with a conventional radiotherapy related to quality of life on the one hand and to evaluate toxicity, re-calcification and stability of vertebral body as well as pain relief and local response for palliative patients with painful spinal bone metastases on the other hand. this is a single-center, prospective randomized controlled trial with parallel-group design to determine the quality of life after rt in patients with spinal bone metastases. two different techniques were evaluated: intensity modulated radiotherapy (imrt) and fractionated conventional external beam rt with 10×3 gy each. experimental intervention: imrt 10 x 3 gy control intervention: 3d-rt 10 x 3 gy after the baseline measurements have been recorded, the patients will be randomly assigned to one of the two groups: imrt 10×3 gy (n = 30) or fractionated conventional 3d-rt 10×3 gy (n = 30). the rt will be applied daily (mondy to friday). follow-up per patient: the target parameters will be measured and recorded at baseline, at the end of rt (t1), and at 12 weeks (t2) and 6 months (t3) after the end of the irradiation period.

Eligibility criteria:
inclusion criteria: * patients with a histologically confirmed tumor diagnosis and with secondary diagnosed solitary/multiple spinal bone metastases * indication for rt of the spinal bone metastases * age of between 18 and 85 years * karnofsky index of at least 50 * signed declaration of informed consent exclusion criteria: * lymphoma * significant neurological or psychiatric disorders, including dementia and epileptic seizures * previous rt at the current irradiation site * other severe disorders that in the judgment of the study director may prevent the patient's participation in the study * lacking or diminished legal capacity * any medical of psychological condition that the study director considers a preventive factor for the patient's ability to complete the study or to adequately understand the scope of the study and to give his or her consent.

Keywords: bony metastases palliative radiotherapy
use of a treatment benefit questionnaire in patients with chronic migraine treated with onabotulinumtoxina (botox®)

Conditions: Chronic Migraine

Summary: this study will evaluate the use of the assessment of chronic migraine impacts (acm-i) questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxina (botox®) in adults with chronic migraine.


Eligibility criteria:
inclusion criteria: * history of chronic migraine for at least 6 months prior to the screening visit * fifteen or more headache days during the 4-week screening period (≥4 headache episodes lasting ≥4 hours and ≥50 % of headache days are migraine) exclusion criteria: * conditions causing chronic facial pain such as temporomandibular disorder (tmd) and fibromyalgia * use of headache prophylaxis medication within 4 weeks of the screening visit * diagnosis of myasthenia gravis, eaton-lambert syndrome, amyotrophic lateral sclerosis * previous use of any botulinum toxin of any serotype for any reason * skin infections or acne that would interfere with the injection sites * acupuncture, transcutaneous electrical nerve stimulation (tens), cranial traction, dental splints for headache, nociceptive trigeminal inhibition, occipital nerve block treatments, or injection of anesthetics/steroids within 4 weeks of screening.
remote symptom collection to improve postoperative care

Conditions: Gastrointestinal Cancer; Gastrointestinal Tumor; Gastrointestinal Tumor Surgery; Gastrointestinal Surgery

Summary: there are vulnerabilities in post-discharge care transition for patients after undergoing resection of malignant gastrointestinal tumors. this study aims to investigate the possibility of utilizing voice-assisted remote symptom monitoring system (varsms) to alleviate some of these challenges.

randomized controlled trial comparing post-op patients randomized to using the varsms vs control.

Eligibility criteria:
inclusion criteria 1. at least 18 years old. ages of subjects \>89 will simply be reported as \>90. 2. scheduled for a gi surgery for management of a tumor in a participating hospital. 3. fluent in oral and written english. 4. has consistent and continued full access to an operational wi-fi for the duration of the study. exclusion criteria 1. unable to provide informed consent. 2. not willing to commit to regular participation in the study to include daily use (40 days) of the study application. 3. life expectancy of less than 60 days. 4. in the opinion of the investigator, participation in this study is contraindicated.

Keywords: speech system large language model ai
a study of the safety and pharmacokinetics of escalating doses of dcdt2980s in patients with relapsed or refractory b-cell non-hodgkin's lymphoma and chronic lymphocytic leukemia and dcdt2980s in combination with rituximab in patients with relapsed or refractory b-cell non hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

Summary: this is a phase i, multicenter, open-label, dose-escalation study of dcdt2980s administered by intravenous (iv) infusion to patients with relapsed or refractory hematologic malignancies. in addition, at selected sites, dcdt2980s will be studied in combination with rituximab.


Eligibility criteria:
inclusion criteria: * life expectancy of at least 12 weeks * history of histologically-documented hematologic malignancy for which no effective standard therapy exists: indolent nhl (including grades 1-3a fl; mzl \[including splenic, nodal, and extra-nodal\]; and sll), grade 3b fl, dlbcl, mcl, or cll * must have at least one bi-dimensionally measurable lesion exclusion criteria: * prior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks prior to study treatment * treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent within 2 weeks prior to of study treatment * completion of autologous stem cell transplant within 100 days prior to study treatment * prior allogeneic stem cell transplant
transdermal clonidine in chronic hemodialysis patients

Conditions: Renal Dialysis

Summary: the majority of chronic hemodialysis patients need a combination of several antihypertensive drugs for adequate bp control. the primary objective of this study is to evaluate whether transdermal clonidine can improve blood pressure control or decrease oral antihypertensive agents type or dosage and the secondary objective is to observe incidence of adverse reactions of transdermal clonidine in chronic hemodialysis patients.

it's a randomised crossover clinical trial. subjects: chronic hemodialysis patients. all subjects will be randomised to 2 groups. subjects in first group will receive 4 weeks transdermal clonidine plus regular antihypertensive agents treatments first, 2weeks wash-out then and 4 weeks antihypertensive agents without transdermal clonidine. the other group will receive 4 weeks antihypertensive agents without transdermal clonidine first, 2weeks wash-out then and 4 weeks transdermal clonidine plus regular antihypertensive agents treatments. ambulatory blood pressure, echocardiography, and biochemistry will be detected.

Eligibility criteria:
inclusion criteria: 1. signed informed consent; 2. age: 18years to 80 years old； 3. on hemodialysis for more than or equal to 3 months, not less than 3 times and 12 hours hemodialysis per week； 4. cardiac function grade i or grade ii(nyha)； 5. using 1 or more than 1 oral antihypertensive drugs, pre-dialysis systolic blood pressure over 140mmhg or dialysis blood pressure over 90mmhg, post-dialysis systolic blood pressure over 130mmhg or diastolic blood pressure over 80mmhg exclusion criteria: 1. acute infection within 1 month； 2. acute myocardial infarction/cardiac function grade iv/stroke within 3months； 3. lvef lower than 50% by echocardiography； 4. dry weight is not suitable by bcm evaluation, more than plus or minus 1kg； 5. inter-dialysis weight gain exceeds 5% of dry weight； 6. post-dialysis systolic blood pressure lower than 120mmhg and diastolic blood pressure lower than 70mmhg； 7. begin or stop recombinant human erythropoietin treatment within 2 weeks before inclusion or 10 weeks after inclusion; 8. adjust recombinant human erythropoietin dosage to more than 2times or less than half original dosage within 2 weeks before inclusion or 10 weeks after inclusion； 9. the treatment regimen will be amended within 10 weeks and it is expected that the treatment amendment may affect blood pressure； 10. pregnancy or lactation or planning a pregnancy in 10 weeks； 11. expected to withdraw hemodialysis treatment in 10 weeks； 12. allergic to clonidine or its accessories； 13. undergoing other clinical studies, and the research interventions have an impact on blood pressure； 14. other clinical conditions that may affect the results

Keywords: renal dialysis hypertension clonidine
effects of prebiotics on gut microbiome in patients undergoing hsct

Conditions: Multiple Myeloma; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Non Hodgkin Lymphoma; Acute Lymphocytic Leukemia; Hodgkin Lymphoma; Hodgkin Disease; Myelofibrosis; Myelodysplastic Syndromes; Myeloproliferative Neoplasm; Sickle Cell Disease; Mantle Cell Lymphoma

Summary: the purpose of this study is to see whether hematopoietic stem cell transplant (hsct) patients can consistently eat a diet rich in prebiotics. this type of diet may be helpful in maintaining diversity in the gastrointestinal (gi) system and therefore potentially decreasing risk of other gi problems.

maintaining gastrointestinal (gi) microbiome diversity has been shown to improve treatment related mortality in hsct patients. interventions to improve gi microbial diversity could be beneficial to this patient population. diets rich in prebiotics have been shown to increase gut microbial diversity and improve symptoms in other gastrointestinal diseases. prebiotics are non-digestible carbohydrates that promote growth of commensal organisms in the gut by providing nutrition. some examples are brown rice, green apples, and tomatoes. our theory is that consuming a diet rich in prebiotics pre- and during the first 100 days following hsct will help to reduce acute graft versus host disease (agvhd) overall, and specifically acute gi gvhd, and clostridium difficile (c.diff). participants will be encouraged to eat at least 2 servings of a prebiotic-rich food from time of admission for hsct through 100 days following hsct and will be clinically monitored, including for acute gvhd, acute gi gvhd and c.diff. stool samples will be collected from all participants about once every 4 weeks.

Eligibility criteria:
inclusion criteria: 1. agreement to adhere to lifestyle considerations(prebiotic diet) throughout study duration 2. adults (≥18 yrs of age) 3. able to provide informed consent 4. are willing/able to incorporate the required foods in their diet 5. eligible, suitable and planning to undergo a stem cell transplant: 1. either allogeneic or autologous 2. with any conditioning regimen (e.g. both myeloablative and reduced intensity conditioning) 3. matched related, matched unrelated, haplo-identical and cord blood transplants will be included. exclusion criteria: 1. patients undergoing a second allogeneic or autologous transplant or an allogeneic transplant after an autologous transplant. 2. anticipation of requirement of broad spectrum antibiotics 1 week prior to admission for hsct (through hsct) 3. patients with any prior history of c.diff infection

Keywords: hematopoietic stem cell transplant stem cell transplant bone marrow transplant gi microbiome